Dasatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), predominantly targets BCR-ABL and SRC oncoproteins and also inhibits off-target kinases, which may result in unexpected drug responses. We identified 22 patients with marked lymphoproliferation in blood while on dasatinib therapy. Clonality and immunophenotype were analyzed and related clinical information was collected. An abrupt lymphocytosis (peak count range 4-20 Â 10 9 /l) with large granular lymphocyte (LGL) morphology was observed after a median of 3 months from the start of therapy and it persisted throughout the therapy. Fifteen patients had a cytotoxic T-cell and seven patients had an NK-cell phenotype. All T-cell expansions were clonal. Adverse effects, such as colitis and pleuritis, were common (18 of 22 patients) and were preceded by LGL lymphocytosis. Accumulation of identical cytotoxic T cells was also detected in pleural effusion and colon biopsy samples. Responses to dasatinib were good and included complete, unexpectedly long-lasting remissions in patients with advanced leukemia. In a phase II clinical study on 46 Philadelphia chromosome-positive acute lymphoblastic leukemia, patients with lymphocytosis had superior survival compared with patients without lymphocytosis. By inhibiting immunoregulatory kinases, dasatinib may induce a reversible state of aberrant immune reactivity associated with good clinical responses and a distinct adverse effect profile.
Introduction
Chronic myeloid leukemia (CML) was the first cancer in which a molecular mechanism (Philadelphia chromosome (Ph) and BCR-ABL fusion gene) causal to malignant transformation was discovered. Targeted inhibition of the oncogenic BCR-ABL tyrosine kinase by novel drugs has profoundly changed the therapy of CML. 1 Imatinib mesylate (Gleevec/Glivec, Novartis, Basel, Switzerland) was the first tyrosine kinase inhibitor (TKI) approved for clinical use and currently is the standard therapy for all phases of CML. 2 The drug has also been included in the treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph þ ALL).
Dasatinib (Sprycel, Bristol-Myers Squibb (BMS), Princeton, NJ, USA) is a second generation TKI approved for clinical use in imatinib resistant CML and Ph þ ALL. [3] [4] [5] The kinase inhibition profile of dasatinib is broad and includes SRC and TEC kinases not inhibited by imatinib. 6, 7 This may be therapeutically advantageous, but as long-term effects on normal cells are largely unknown, significant side effects may emerge.
Thus far, the toxicity profile of TKIs has been favorable and only minor low-grade side-effects have been observed. However, some patients have experienced unexpected consequences from the therapy, such as altered bone mineral metabolism. 8 These have been attributed to the off-target effects of the drug.
Recently, several in vitro studies have indicated profound inhibitory effects of dasatinib on T-and NK-cell activation and proliferation. [9] [10] [11] [12] The putative in vivo immunomodulatory effects of dasatinib have thus far not been explored.
In a proportion of CML and Ph þ ALL patients, we observed a significant expansion of large granular lymphocyte (LGL) cells during dasatinib therapy. For a more comprehensive analysis, a larger case series was collected from different centers in the United States and Europe, and the clinical and biological aspects of dasatinib-associated blood lymphoproliferation were assessed. In addition, dasatinib-associated lymphocytosis was analyzed in a separate cohort of 46 Ph þ ALL patients treated in an international phase II study. We show that LGL lymphocytosis is a clonal expansion of cytotoxic T-or NK-cells, which occurs in a distinct subset of patients sharing common clinical and biological features. We propose that the expansion of cytotoxic lymphocytes is associated with excellent therapy responses and autoimmune-like adverse reactions.
Patients and methods

Study patients I
A total of 22 Ph þ leukemia patients were identified by contacting several investigators in Europe and the United States with expertize on Ph þ leukemia and dasatinib therapy. The inclusion criteria were an absolute increase in lymphocyte count (43.6 Â 10 9 /l, or institutional upper normal limit) with LGL morphology during dasatinib therapy. Most of the patients (n ¼ 13) were treated within clinical study protocols of BristolMyers Squibb. Dasatinib was administered as monotherapy, usually at doses of 70 mg twice daily and dose reductions were made in case of toxicity. A total of 17 patients had CML; 12 with chronic phase, two with accelerated phase and three with blastic phase. Five patients had Ph þ acute lymphoblastic leukemia (ALL) (see Table 1 for patient characteristics). Eight 
Study patients II (START-L cohort)
START-L is an open-label, international, multicenter study sponsored by Bristol-Myers Squibb investigating the response durability of dasatinib in imatinib-resistant or intolerant patients with Ph þ ALL (n ¼ 46). In this separate patient cohort, the prevalence of lymphocytosis was evaluated. A patient was defined to have a lymphocytosis if an absolute blood lymphocyte count of 43.6 Â 10 9 /l was observed on more than one occasion after more than 4 weeks of dasatinib therapy. In addition, the influence of lymphocytosis on overall and progression-free survival was assessed, but only in a descriptive manner as the study was not originally designed and powered for a formal analysis.
Clinical laboratory analyses
Results of routine laboratory tests (blood cell counts, differential analysis of leukocytes) were obtained from the patients earlier and during the dasatinib therapy. Plasma genome load of cytomegalovirus (CMV) and Epstein Barr virus (EBV) was detected by real-time quantitative PCR. The human leukocyte antigen (HLA) typing was performed using normal serological or PCR-based methods. Peripheral blood (PB) leukocyte morphology was analyzed from May-Grü nwald-Giemsa stained smears.
Immunophenotyping of PB lymphocytes
Immunophenotyping was done with flow cytometry using antibodies against the following antigens: CD3, CD4, CD8, CD16/56, CD45, CD56, CD57, HLA-DR, CD62L, CD45RA, CD45RO, T-cell receptor (TCR) -a/b and TCR-g/d with isotype controls.
Regulatory T cells were analyzed with four-color flow cytometry using CD3, CD4, CD25 and FOXp3 (eBioscience, San Diego, CA, USA) antibodies. The results are shown as percentage of positive cells from CD3 þ CD4 þ T-helper cells. In addition, blood samples from 15 healthy controls were studied.
The antibodies were purchased from BD Biosciences (San Jose, CA, USA) if not otherwise mentioned. The analyses were performed with four-color flow cytometer (FACS Calibur, BD, Franklin, Lakes, NJ, USA).
These CMV or EBV antigen specific T cells were determined with HLA-A2 pentamers conjugated with PE-fluorochrome according to the manufacturer's instructions (Proimmune, Oxford, UK).
Immunohistochemistry
Immunohistochemical analyses were performed on colon biopsies from two patients with colitis. In brief, sections were stained for connective tissue (HERO) and with antibodies recognizing specific subsets of lymphocytes (CD3, CD4, CD8, CD56 and CD20). CMV þ cells were detected by staining with an anti-CMV antibody.
Cytogenetic and molecular genetic analysis
The rearrangement of TCR-g/d genes was analyzed by PCR with routine procedures used in the clinical laboratories. Molecular genetic analysis of BCR-ABL transcripts was performed with real-time quantitative PCR. The cytogenetic response was assessed using conventional G-banding technique.
Statistical analysis
Progression free survival and overall survival were calculated using a Kaplan-Meier estimator. Statistical significance of differences in continuous variables was assessed by the MannWhitney U test.
Results
Clinical features of lymphocytosis
Patient characteristics are described in Table 1 . All patients had earlier been exposed to imatinib, but similar changes in lymphocyte count or morphology had not been observed. On dasatinib, the median time to lymphocytosis was 3 months from the start of treatment (range 1-15 months). It typically developed abruptly, with a peak lymphocyte count ranging from 4 to 20 Â 10 9 /l, and was often preceded by low-grade fever without focal signs of infection ( Figure 1 ). In the leukocyte differential count, the majority (450%) of PB lymphocytes were large and granular with typical LGL morphology (normal range for LGL cells is 10-15%. 13 ) In most patients, LGL lymphocytosis was long lasting and continued throughout dasatinib therapy, albeit with marked fluctuations in absolute lymphocyte count ( Figure 1 ). The longest on-therapy follow-up has lasted for 30 þ months. In all evaluable patients (n ¼ 4), lymphocyte counts normalized after drug discontinuation.
Characterization of lymphocytes
The predominant immunophenotype in 15 patients was CD3 þ CD8 þ cytotoxic T-cell and in seven patients a CD3negCD16/ 56 þ NK-cell phenotype (Table 2 ). CD3 þ CD8 þ cells also displayed activation markers, including HLA-DR and CD57 (Supplementary Figure 1) and had TCR-a/b chains on the cell surface. CD8 þ T cells showed low expression of CD62L antigen with a median number of positive cells of 9% (range 5-14%).
All patients with a T-LGL phenotype showed a mono/ oligoclonal rearrangement in TCR-g/d genes by PCR (Table 2) . In patients with an earlier hematopoietic stem cell transplantation, the clonal LGL cells were of donor origin and no similar rearrangement of TCR-g/d was detected in donor cells before transplantation (n ¼ 1).
CMV and EBV genome load in blood and virus-specific T cells
Modest CMV reactivation was observed in 9 of 22 patients. In selected patients, CMV genome load in blood paralleled lymphocyte counts (data not shown), but CMV reactivation usually resolved without specific antiviral treatment.
The amount of CMV or EBV specific lymphocytes was analyzed from a subset of patients (n ¼ 6). The median percentage of CMV-specific T cells was 1.0 (ranging from 0.5 to 12%) in one chronic phase CML patient. CMV genome was not detected by PCR in the PB sample taken on the same day. None of the studied patients had elevated numbers of Dasatinib-associated clonal lymphoproliferation S Mustjoki et al EBV-specific cytotoxic T cells (median 0.1%, range 0-0.4%) or increased EBV genome copy numbers in plasma.
Regulatory T cells
Compared with healthy controls (n ¼ 15) or to dasatinib patients without LGL lymphocytosis (n ¼ 6), the patients with LGL lymphocytosis (n ¼ 7) had significantly lower percentage of regulatory T cells in PB (median 5.1%, 4.3%, 1.9% calculated from CD4 þ T cells, respectively, Po0.001) (Figure 2a ).
Major histocompatibility complex (MHC) class I association
HLA tissue geno/phenotyping was done from blood lymphocytes of 18 patients. Of these, 15 had at least one HLA-A2 allele Table 1 ) in a dasatinib patient with LGL lymphocytosis.
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Control patients
In control patients (n ¼ 8), the lymphocyte count remained normal during dasatinib therapy (Supplementary Table 3 and Figure 1 ). Three of eight control patients had, however, increased proportion of LGL cells in PB (450% of lymphocytes), which were found to be clonal by TCR-g/d gene assay (Supplementary Table 3 ). Only four of eight control patients had the HLA-A2 allele.
Adverse effects during dasatinib therapy
Dasatinib-related severe (grade III-IV) adverse effects were common. Pleural effusions and/or pulmonary infiltrates were seen in 13/22 patients, colitis in 11/22 patients and long-lasting mild fever with no infectious focus in 14/22 patients ( Table 1) . Adverse effects were temporally related to dasatinib therapy and emerged after the appearance of LGL lymphocytosis. In 10 of 11 patients who encountered colitis, lymphocytosis had been detected before the development of colitis. Similarly, 11 of 13 patients with pleural effusions and/or pulmonary infiltrates had lymphocytosis before pleural adverse effects. Despite frequent side effects, only 4 of 22 patients had to discontinue dasatinib treatment. Pleural fluid immunophenotyping was available from three patients with T-LGL lymphocytosis. Lymphocytosis was also observed in pleural fluid samples and the majority of the cells were CD3 þ CD8 þ CD57 þ T cells (Figure 2b) . No leukemic cells were detected. In one patient analyzed by allele-specific TCR-g primers (patient 6, Table 1 and 2), an identical CD8 þ T-cell clone was observed both in peripheral blood and in pleural fluid. The clone persisted in follow-up samples obtained even after 12 months after the start of lymphoproliferation.
Immunohistochemistry was performed from colonoscopy biopsies of two patients with severe colitis during dasatinib therapy (patients 1 and 14, Table 1 ). Significant infiltration of CD8 þ T cells was detected (Figure 2c ). Markers for other lymphocyte antigens (CD19, CD4 and CD56) were negative.
None of the control patients had pleuritis or colitis during dasatinib therapy.
Response to dasatinib therapy
All patients with relapsed Ph þ ALL (n ¼ 5) and blastic phase CML (n ¼ 3) achieved complete molecular response (CMR) during dasatinib therapy. The responses were also durable, more than 18 months in three patients with Ph þ ALL (therapy still continuing and patients are in CMR) (Table1 and Figure 1) . The therapy outcome in chronic phase CML patients was also good; four patients with CMR, five patients with major molecular response and two patients with complete cytogenetic response ( Table 1) .
Data from a phase II cohort (START-L)
A total of 46 imatinib intolerant or resistant patients with Ph þ ALL were treated with dasatinib in an international, BristolMyers Squibb-sponsored phase II trial with a follow-up of 24 months. Lymphocytosis was defined as an increased (43.6 Â 10 9 /l) absolute blood lymphocyte count in at least two occasions after at least 4 weeks of dasatinib therapy. Based on these criteria, 6 of 46 patients (13%) had lymphocyte proliferation during dasatinib treatment. Median progression free survival was 2.7 months in patients without lymphocytosis (Figure 3a) , whereas no median progression free survival was reached in the patients with lymphocytosis during 24-month follow-up time. Similarly overall survival was superior in patients with lymphocytosis compared with patients without lymphocytosis (no median time reached vs 5.8 months, respectively) (Figure 3b ).
Discussion
In this study, we report a marked clonal lymphoproliferation caused by persistent expansion of cytotoxic T-or NK-LGL cells in a distinct group of patients receiving dasatinib therapy for CML or Ph þ ALL.
In recent years, several new small molecule TKIs have emerged and have shown promising clinical activity. Despite their relative target specificity, many second line TKIs also possess a wide-spectrum inhibitory profile on the kinome. The inhibited kinase(s) responsible for LGL expansion noted in this study are unknown. Current small molecule kinase inhibitors have both overlapping and distinct target kinase profiles. It is noted that none of the patients had similar phenomenon during earlier imatinib treatment. Based on a proteomic screen on the difference between kinase inhibition of these two TKIs, putative targets include Lck, Btk, Tec, EphB4, Lyn, Fyn, Hck, Zak and Src. 7, 9, 14, 15 Some off-target effects of TKIs have already been reported, such as hypophosphatemia 8 during imatinib therapy. A case report linked non-bacterial panniculitis to dasatinib therapy, putatively through an immune-mediated mechanism. 16 Pleural effusion is a common dasatinib-related adverse-effect, particularly in patients with advanced disease in whom incidence up to 20% has been reported. 17 Interestingly, recent studies have suggested that dasatinib induced pleural effusions may be immune mediated. [18] [19] [20] These observations are concordant with our results, as almost all our patients with LGL proliferation had pleural effusions or pneumonitis. Analysis of lymphocytes from pleural fluid showed a similar phenotype (CD3 þ CD8 þ CD57 þ ) and genotype (identical T-cell clone) as simultaneously observed in peripheral blood. Furthermore, a significant proportion (11 of 22) of our patients had colitis, which in some cases was severe. Colon biopsies from two patients showed submucosal infiltration of cytotoxic CD3 þ CD8 þ T cells.
Large granular lymphocyte lymphocytosis preceded in most patients the occurrence of pleuritis and colitis implying a temporal relationship. No clonal LGL proliferation has been reported in the literature with colitis or pleuritis caused by other factors. Furthermore, the prevalence of grade III-IV diarrhea has been reported to be much lower (8%) in dasatinib clinical studies 17 and none of our eight control patients without LGL lymphocytosis during dasatinib treatment encountered colitis or pleuritis. This suggests that the adverse effects were causally related to LGL lymphoproliferation by virtue of autoimmune reactivity of the expanded cytotoxic LGL cells.
The prognosis of Ph þ ALL or advanced CML relapse after allogeneic stem cell transplantation is often extremely poor with a life expectancy measured in weeks. In our patient population, we had eight such heavily pretreated relapsed patients and all achieved CMR with dasatinib in conjunction with LGL lymphocytosis. Three of these patients are still in CMR after 418 months of treatment.
The notion of prognostically favorable effect of LGL lymphoproliferation was supported by an analysis of a separate cohort of 46 relapsed Ph þ ALL patients treated in an international phase II study. Progression free survival and overall survival were longer in patients who developed peripheral blood lymphoproliferation during dasatinib treatment as compared with those patients without lymphocytosis. Thus far, long-lasting responses in relapsed Ph þ ALL have only been obtained by allogeneic hematopoietic stem cell transplantation.
Recent preclinical in vitro data have indicated a profound inhibitory effect of dasatinib on T-cell activation and proliferation. [9] [10] [11] [12] To resolve the discrepancy between the in vitro and our in vivo data, we hypothesize that in a proportion of dasatinib treated patients, off-target kinase inhibition results in hyperreactivity of terminal memory CD8 þ T cells or NK cells on antigen challenge (for example, CMV) owing to activation through an alternative, non-TCR-dependent pathway (for example, IL-2R -mediated). Lower proportion of regulatory T cells in these patients may contribute to the enhanced immune reactivity. Owing to strong MHC class I association, the hyperreactivity is likely to be genetically mediated (for example, KIR-receptor genotype). Further studies pinpointing the mechanisms, such as the epitopes of the expanded cytotoxic cells and genotype differences, are ongoing.
The assessment of prevalence of LGL lymphoproliferation during dasatinib therapy requires an analysis of a larger patient cohort. In one of the current study centers (Helsinki), 17 patients were enrolled in phase II studies on dasatinib and seven patients (40%) developed clonal LGL lymphocytosis. However, clonal T cells were also detected in three of the 10 patients with normal LGL lymphocyte counts. In a separate patient cohort of 46 patients with Ph þ ALL, lymphocytosis was observed in 13% of patients during 24 months follow-up.
In conclusion, we show that marked clonal expansion of cytotoxic LGL cells seemed to be in a significant proportion of dasatinib treated patients. Although the mechanisms currently are unresolved, the phenomenon is clinically relevant and may have both beneficial (anti-leukemic response) and harmful (antihost reactivity) sequelae. This warrants further laboratory and clinical studies in larger patient populations and may result in novel applications for TKIs.
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